Welcome to our dedicated page for CytoMed Therapeutics SEC filings (Ticker: GDTC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CytoMed Therapeutics Limited filings document foreign private issuer disclosures for a clinical-stage cell therapy company. Form 6-K reports furnish clinical and regulatory updates for CAR γδ T cell, iPSC-derived γδ NKT cell, γδ T cell, and cord blood-derived Natural Killer cell programs, along with annual financial results and research expense disclosures.
The filing record also covers annual general meeting materials, proxy voting items, subsidiary structure changes, completed technology and asset acquisitions, non-dilutive subsidiary financing, and shareholder communication matters. These documents frame CytoMed's governance, capital resources, development spending, and corporate organization across Singapore and Malaysia.
CytoMed Therapeutics Limited (GDTC) prospectus supplement (Form 424B5) provides table-of-contents items and partial financial and capitalization data related to an offering and pro forma adjustments. The filing shows ordinary shares outstanding of 11,540,000 on an actual basis, 11,836,348 pro forma and 14,268,520 as adjusted (assuming 2,432,172 shares issued in the offering). Total liabilities are presented as 1,023,960 and 749,495 (two comparative figures). Accumulated losses are shown as (14,848,135) and (10,868,200) with pro forma accumulated losses of (16,224,695) and (11,875,783). Total capitalization appears as 10,067,749 and 7,369,162 with an as-adjusted capitalization of 15,587,229 and 11,409,185. Net tangible assets are reported as 8,950,739 and 6,551,558 and as-adjusted 14,470,219 and 10,591,581, with net tangible asset per share figures around $0.78, $0.57, and as-adjusted $1.01/$0.74. The supplement also includes Malaysian tax rate references (examples: 17%, 24%, royalties 10%, interest 15%, dividends exempt). Much of the provided text is a table of contents and fragmented table rows rather than full narrative disclosure.
CytoMed Therapeutics (GDTC) filed a Form 6-K to furnish a 21 Jul 2025 press release. The company has completed Dose Level 1 of its first-in-human Phase I dose-escalation “ANGELICA” trial of CTM-N2D, an investigational cell therapy for patients with advanced solid tumours or haematological malignancies, and has been cleared to begin Dose Level 2. The milestone indicates initial safety/tolerability at the starting dose, a prerequisite for further escalation and eventual efficacy assessment.
The filing contains no financial data, guidance, or corporate transactions; its sole purpose is to publicly disclose this clinical progress (Exhibit 99.1). Investors should view the news as an early-stage, non-pivotal signal of programme momentum rather than a determinant of near-term revenue.
CytoMed Therapeutics has received Notice of Effectiveness from the SEC for its Form F-3 registration statement (File No. 333-288033), effective as of June 23, 2025, at 4:00 P.M.
Form F-3 is a securities registration statement used by foreign companies that are already listed on a U.S. exchange and meet certain eligibility requirements. This effectiveness notice indicates that CytoMed can now proceed with its planned securities offering as outlined in the registration statement.
The effectiveness of this F-3 filing suggests that CytoMed may be planning to:
- Raise additional capital through securities offerings
- Register securities for potential future offerings
- Enhance its financial flexibility for future growth initiatives
CytoMed Therapeutics Limited (NASDAQ: GDTC) has filed a Form 144 indicating the proposed sale of 81,482 ordinary shares, valued at roughly $171,112 based on the market price disclosed in the filing. The seller—whose name is not provided in the excerpt—plans to execute the transaction through Bank of Singapore on or about 23 June 2025. The company has 11.54 million shares outstanding, so the notice represents approximately 0.7 % of total shares.
The securities were originally acquired via a share subscription on 22 April 2021. The filing also discloses that the same holder has sold 4,928 shares over the past three months, generating aggregate gross proceeds of $11,548.72. No adverse, non-public information is claimed to be known by the seller, as required under Rule 144 representations.
While Form 144 filings do not guarantee that a sale will occur, they signal the intent of an affiliate or insider to liquidate shares. Investors often monitor such filings as a gauge of insider sentiment and potential stock-supply overhang. The transaction size is modest relative to the public float, but it may still weigh on short-term sentiment given GDTC’s limited trading volume as a small-cap biotech.